Invest now
IPCA Laboratories share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹1,951.00(-0.42%)September 8, 2026 15:29:55 PM IST
- NSE
- BSE
- Vol : 171.31 K (NSE + BSE)Last 20 day avg : 789.60 K
IPCA Laboratories is trading -0.42% lower at Rs 1,951.00 as compared to its last closing price. IPCA Laboratories has been trading in the price range of 1,988.75 & 1,951.00. IPCA Laboratories has given 38.07% in this year & -0.80% in the last 5 days. IPCA Laboratories has TTM P/E ratio 32.95 as compared to the sector P/E of 37.01.There are 16 analysts who have initiated coverage on IPCA Laboratories. There are 7 analysts who have given it a strong buy rating & 5 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.The company posted a net profit of 401.89 Crores in its last quarter.Listed peers of IPCA Laboratories include Sun Pharmaceutical Industries (-0.98%), Divi's Laboratories (2.85%), Torrent Pharmaceuticals (1.01%).The Mutual Fund holding in IPCA Laboratories was at 31.15% in 30 Jun 2026. The MF holding has decreased from the last quarter. The FII holding in IPCA Laboratories was at 10.72% in 30 Jun 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 08 Sep 2026, 08:41 PM IST
- BetaLow volatility0.29Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.10The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.31Annual dividends as a percentage of the stock price.
- P/BHigher than historical values6.18The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values38.07Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates Fair Valuation1.11The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
IPCA Laboratories News
IPCA Laboratories Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,881.10 | -0.98 | 4,51,328.27 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,570.55 | 2.85 | 2,54,068.03 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,962.75 | 1.01 | 1,88,760.31 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,383.95 | -0.86 | 1,11,803.57 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,150.00 | -0.43 | 1,14,712.94 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allIPCA Laboratories Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-13 | Quarterly Results |
| 2026-05-29 | Audited Results & Dividend |
| 2026-02-13 | Quarterly Results |
| 2025-11-13 | Quarterly Results |
| 2025-08-11 | Quarterly Results |
About the company IPCA Laboratories
- IndustryBiotechnology & Drugs
- ISININE571A01038
- BSE Code524494
- NSE CodeIPCALAB
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
IPCA Laboratories Share Price FAQs
IPCA Laboratories is trading at 1951.00 as on Tue Sep 08 2026 09:59:55. This is -0.42% lower as compared to its previous closing price of 1959.15.
The market capitalization of IPCA Laboratories is 49440.97 Cr as on Tue Sep 08 2026 09:59:55.
The average broker rating on IPCA Laboratories is Buy. The breakup of analyst rating is given below -
- 7 analysts have given a strong buy rating
- 5 analysts have given a buy rating
- 2 analysts have given a hold rating
- 1 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for IPCA Laboratories is 1999.00 whereas the 52 wk low is 1252.95
IPCA Laboratories can be analyzed on the following key metrics -
- TTM P/E: 32.95
- Sector P/E: 37.01
- Dividend Yield: 0.31%
- D/E ratio: -
IPCA Laboratories reported a net profit of 1141.12 Cr in 2026.
The Mutual Fund Shareholding was 31.15% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
IPCA Laboratories QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.